💊 Medical & Pharmaceutical Updated August 2026

Elmiron Lawsuit: The Vision-Loss and Maculopathy Claims

Lawsuits allege the bladder-pain drug Elmiron caused a retinal eye condition, pigmentary maculopathy, and that the maker failed to warn. The cases are consolidated in a federal MDL.

Category

Medical & Pharmaceutical

Coverage

Active (MDL)

Last Updated

August 2026

Content Type

Legal Analysis

What the Lawsuits Allege

Elmiron (pentosan polysulfate sodium) is a drug long prescribed for interstitial cystitis, a painful bladder condition. Lawsuits allege that long-term use can cause pigmentary maculopathy — damage to the retina that can blur vision, impair night sight and, in some cases, cause lasting vision loss — and that the manufacturer, a Janssen (Johnson & Johnson) unit, failed to warn patients and doctors for years.

The manufacturer added a maculopathy warning to the label in 2020, which plaintiffs cite as evidence the risk was knowable earlier.

The MDL Status

The federal cases are consolidated in a multidistrict litigation in the District of New Jersey, with hundreds of cases pending. New filings have slowed and settlement discussions have been reported in the background, though no global settlement has been announced and the drug has not been recalled. Causation — tying a patient’s specific eye damage to the drug rather than other causes — is the central contested question.

As with other pharmaceutical MDLs, expert rulings on causation will heavily shape outcomes.

What Patients Should Know

Anyone who took Elmiron long-term and has vision changes should see an eye specialist; a retinal exam is both a health priority and the key evidence for a claim. This page is legal-news coverage, not medical advice. There is no approved settlement fund yet, so treat “sign up for your payout” sites as lead capture.

Before You Act

Thinking About Filing a Claim?

Most plaintiff lawyers offer a free initial consultation and work on contingency, meaning no fee unless there is a recovery. LawsuitWatch is not a law firm: we publish explainers, and we do not provide legal advice, representation or referrals. Your state bar directory is the reliable place to find and verify a lawyer.

Elmiron Pharmaceutical Product Liability

Elmiron Lawsuit: The Vision-Loss and Maculopathy Claims: Frequently Asked Questions

Answers to the most common questions about this case and your legal options.

What eye problem is linked to Elmiron?

Lawsuits link long-term Elmiron use to pigmentary maculopathy, a retinal condition that can cause blurred vision, difficulty with night vision and, in some cases, lasting vision loss.

Is there an Elmiron settlement?

Not a global one. The cases are in an active New Jersey MDL with settlement talks reported in the background. The drug has not been recalled.

What should I do if I took Elmiron?

If you have vision changes, see an eye specialist for a retinal exam. It is both a health priority and the central evidence for any claim.

LawsuitWatch Legal Research Team

Medical & Pharmaceutical Litigation Desk

LawsuitWatch publishes plain-language explainers on active consumer litigation: what a case alleges, who it may affect, and what the process involves. We are not a law firm and do not provide legal advice or representation. Where a figure or filing matters to a decision you are making, verify it against the court record or the official settlement administrator before relying on it. Last updated: August 2026.